XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44.008)

Jacqueline French,Constanza Luzon-Rosenblut,Emilio Perucca,Jenny Qian,Christopher Kenney,Michael Rogawski,Cynthia Harden,Martin Brodie,Roger Porter,Gregory Beatch

doi:10.1212/wnl.0000000000203823

XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44.008)

Jacqueline French, Constanza Luzon-Rosenblut + Show 8 more

https://doi.org/10.1212/wnl.0000000000203823

Copy DOI

Export

Save

Cite

Journal: Neurology

Publication Date: Apr 25, 2023

Affiliation: New York University, Xenon Pharmaceuticals (Canada), Austin Health, University of Melbourne, Monash University, University of California, Davis, University of Glasgow, University of Pennsylvania

#Received Research Support #Pharmaceuticals Inc #Open-label Extension #Advisory Board #Phase 2b Study In Patients #Double-blind Period #Treatment Emergent Adverse Events #Epilepsy Foundation #Scientific Advisory #Changes In Laboratory Findings

Abstract
Full-Text
Similar Papers

Abstract

Listen

XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44.008)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Neurology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44.008)